Key result
PRO-based monitoring identifies regimen-specific adverse event profiles and persistent symptoms months after breast cancer chemotherapy.
Why the study?
Patient-reported outcomes are thought to capture persistent symptoms that are often underestimated in conventional clinical practice.
Does PRO-based monitoring capture persistent adverse events after perioperative chemotherapy in breast cancer patients?
Does PRO-based monitoring capture persistent adverse events after perioperative chemotherapy in breast cancer patients?
Incorporating structured PRO-based questionnaires into follow-up care reveals persistent symptoms beyond chemotherapy completion, which may be crucial for optimizing supportive management.
May optimize supportive management via PRO integration in follow-up; extends evidence on persistent post-chemotherapy toxicities.
PROs are thought to capture persistent symptoms that are often underestimated in conventional clinical practice. In the present breast cancer series, PRO-based monitoring revealed regimen-specific AE profiles and the persistence of neuropathy, dysgeusia, and nail changes beyond chemotherapy. These findings highlight the importance of monitoring not only during chemotherapy, but also in the months after the chemotherapy's completion, when patients continue to suffer from persistent symptoms. Incorporating structured PRO-based questionnaires into follow-up care may be crucial for optimizing supportive management.
No takes yet. Share an insight, caveat, or question.
FUJII et al. (2026) studied this question. PRO-based monitoring identified regimen-specific adverse event profiles and persistence of neuropathy, dysgeusia, and nail changes months after breast cancer chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: